Abstract:e15051 Background: Paclitaxel and S-1 are both effective anti-tumor agents in advanced gastric cancer. However, the continuous administration of S-1 for three weeks or more can result in unacceptable toxicities. Therefore, an alternative treatment schedule (one-week administration followed by a one-week rest) is warrant for testing in order to allow continuation of the therapy. We evaluate the efficacy and safety of biweekly paclitaxel and S-1(SPA) as first-line combination therapy in patients with metastatic or locally advanced gastric cancer. Methods: Forty-four Chinese patients(pts) have been included. 33 were male and 11 were female. Median age was 60 years (24-78). 90.1% had ECOG 0 and 1 and. 9 (20.4%) had locally advanced disease and 35 (79.6%) metastatic disease. Pts were administered intravenously paclitaxel at a dose of 120 mg/m2 on day 1 and oral S-1 twice daily (BSA < 1.25 m2, 80 mg/day; 1.25 < or = BSA < 1.50 m2, 100 mg/day; 1.50 m2< or = BSA, 120 mg/day) on days 1-7 followed by a drug-free interval of 1 week every 14-day cycle. A total of 277 chemotherapy cycles were administered, with a median of 6 cycles per patient (range 1-12), and 19 (43.2%) pts received up to seven cycles. 34 pts (77.2%) received second-line treatment. Results: Of the 44 eligible pts, the ORR was 38.6% with PR in 17 pts, SD in 20 pts s and PD in 6 pts. The median PFS and median OS were 5.2 months (95% CI: 4.08-6.39 months) and 12.2 months (95% CI: 8.81-15.60 months) , respectively, The major hematological toxicities were grade 3 leucocytopenia in 2 pts (4.5%), grade 3 neutropenia in 14 pts (40.9%) and grade 4 in 4 pts (9.0%). Two pts (4.5%) suffered grade 1 febrile neutropenia. The grade 3/4 nonhematological toxicities, such as nausea, vomiting, alopecia, diarrhea, neurological toxicity and fatigue accounted for 4.5%, 6.8%, 4.5%, 2.2%, 2.2% and 6.8%, respectively. Conclusions: Biweekly paclitaxel and S-1(SPA regimen) combination therapy had promising activity with acceptable toxicities. SPA regimen was easy to implement and more patients received second-line chemotherapy. A well-designed randomized phase III study is needed to compare this regimen with other S-1-based combination treatments. Clinical trial information: 85705844.

Hepatic Arterial Infusion Oxaliplatin Plus Oral S-1 Chemotherapy in Gastric Cancer with Unresectable Liver Metastases: A Case Series and Literature Review

Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases

A Pilot Study of Hepatic Arterial Infusion of Chemotherapy for Patients with Advanced Hepatocellular Carcinoma Who Have Failed Anti‐angiogenic Therapy

Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma.

Hepatic Artery Infusion and Systemic XELOX Chemotherapy for Gastric and Colorectal Cancer with Liver Metastasis:Analysis of Curative Effect and Safety

Efficacy of Oxaliplatin Combined with Pirarubicin and 5-Fluorouracil for Advanced Hepatocellular Carcinoma

Hepatic Arterial Infusion of Chemotherapy As a Salvage Therapy for Patients with Advanced Hepatocellular Carcinoma

Hepatic Arterial Infusion with Irinotecan, Oxaliplatin, and Floxuridine Plus Systemic Chemotherapy As First-Line Treatment of Unresectable Liver Metastases from Colorectal Cancer

Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report

Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases

[Two Cases of Colon Cancer with Severe Liver Dysfunction Due to Multiple Liver Metastases Effectively Treated with Hepatic Arterial Infusion Chemotherapy plus CetuximabFollowed by Systemic Chemotherapy]

Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma

Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer

Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study

Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.

Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma

A pathological complete response to capecitabine plus oxaliplatin regimen combined with tislelizumab in advanced gastric cancer with liver metastases: A case report